Abstract
In summary, we found that no-reflow occurred in 4% of our patients who had undergone interventional procedures during a 5-month period, and were more common in patients with vein grafts or in those who had newer interventional devices. Intracoronary diltiazem led to prompt improvement in coronary blood flow in most patients and was well tolerated.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
